WO2018112365A3 - Methods of treating colorectal cancer and melanoma using parabacteroides goldsteinii - Google Patents

Methods of treating colorectal cancer and melanoma using parabacteroides goldsteinii Download PDF

Info

Publication number
WO2018112365A3
WO2018112365A3 PCT/US2017/066713 US2017066713W WO2018112365A3 WO 2018112365 A3 WO2018112365 A3 WO 2018112365A3 US 2017066713 W US2017066713 W US 2017066713W WO 2018112365 A3 WO2018112365 A3 WO 2018112365A3
Authority
WO
WIPO (PCT)
Prior art keywords
melanoma
methods
colorectal cancer
parabacteroides goldsteinii
treating colorectal
Prior art date
Application number
PCT/US2017/066713
Other languages
French (fr)
Other versions
WO2018112365A2 (en
Inventor
Brian Goodman
Peter SANDY
Jacqueline PAPKOFF
Holly PONICHTERA
Maria SIZOBA
Mark BODMER
Original Assignee
Evelo Biosciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evelo Biosciences, Inc. filed Critical Evelo Biosciences, Inc.
Publication of WO2018112365A2 publication Critical patent/WO2018112365A2/en
Publication of WO2018112365A3 publication Critical patent/WO2018112365A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Provided herein are methods and compositions related to Parabacteroides goldsteinii useful as therapeutic agents for the treatment of colorectal cancer and/or melanoma.
PCT/US2017/066713 2016-12-16 2017-12-15 Methods of treating colorectal cancer and melanoma using parabacteroides goldsteinii WO2018112365A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662435603P 2016-12-16 2016-12-16
US62/435,603 2016-12-16

Publications (2)

Publication Number Publication Date
WO2018112365A2 WO2018112365A2 (en) 2018-06-21
WO2018112365A3 true WO2018112365A3 (en) 2018-09-20

Family

ID=60991551

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2017/066713 WO2018112365A2 (en) 2016-12-16 2017-12-15 Methods of treating colorectal cancer and melanoma using parabacteroides goldsteinii

Country Status (1)

Country Link
WO (1) WO2018112365A2 (en)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
CN108138122B (en) 2014-12-23 2021-09-21 4D制药研究有限公司 Immune regulation
JP6427278B2 (en) 2014-12-23 2018-11-21 フォーディー ファーマ リサーチ リミテッド４Ｄ Ｐｈａｒｍａ Ｒｅｓｅａｒｃｈ Ｌｉｍｉｔｅｄ pirin polypeptide and immune modulation
DK3240554T3 (en) 2015-06-15 2019-10-28 4D Pharma Res Ltd BLAUTIA STERCOSIS AND WEXLERAE FOR USE IN TREATMENT OF INFLAMMATORY AND AUTO-IMMUNE DISEASES
MA41060B1 (en) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprising bacterial strains
MA41010B1 (en) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprising bacterial strains
SG10201912319SA (en) 2015-06-15 2020-02-27 4D Pharma Res Ltd Compositions comprising bacterial strains
HUE045413T2 (en) 2015-06-15 2019-12-30 4D Pharma Res Ltd Compositions comprising bacterial strains
NZ742787A (en) 2015-11-20 2020-02-28 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520631D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520638D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201612191D0 (en) 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
ES2731579T3 (en) 2016-03-04 2019-11-18 4D Pharma Plc Compositions comprising bacterial blautia strains to treat visceral hypersensitivity
TW201821093A (en) 2016-07-13 2018-06-16 英商４Ｄ製藥有限公司 Compositions comprising bacterial strains
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
CA3058943C (en) 2017-04-03 2023-10-17 Gusto Global, Llc Rational design of microbial-based biotherapeutics
RS61872B1 (en) 2017-05-22 2021-06-30 4D Pharma Res Ltd Compositions comprising bacterial strains
JP6978514B2 (en) 2017-05-24 2021-12-08 フォーディー ファーマ リサーチ リミテッド4D Pharma Research Limited Composition containing bacterial strain
PT3638271T (en) 2017-06-14 2021-01-05 4D Pharma Res Ltd Compositions comprising bacterial strains
HRP20220747T1 (en) 2017-06-14 2022-10-14 4D Pharma Research Limited Compositions comprising bacterial strains
WO2019215345A1 (en) 2018-05-11 2019-11-14 4D Pharma Research Limited Compositions comprising bacterial strains
EP3866821B1 (en) 2018-10-15 2024-02-28 PharmaBiome AG Consortia of living bacteria useful for treatment of colorectal cancer
TWI733222B (en) * 2018-10-31 2021-07-11 星聚樊生物科技有限公司 Use of parabacteroides goldsteinii for treating lung cancer
CN112930407A (en) * 2018-11-02 2021-06-08 加利福尼亚大学董事会 Methods of diagnosing and treating cancer using non-human nucleic acids
CA3122347A1 (en) 2018-12-12 2020-06-18 4D Pharma Research Limited Compositions comprising parabacteroides bacterial strains for treating cancer
CN111481565B (en) * 2019-01-25 2021-10-01 星聚樊生物科技有限公司 Use of lipopolysaccharide of paradisella gordonii for pharmaceutical composition for inhibiting inflammatory reaction
CN110279862B (en) * 2019-07-09 2022-04-08 上海市第六人民医院 Anticancer composition and application thereof in preparing medicine for treating osteosarcoma
TW202216169A (en) * 2020-10-27 2022-05-01 星聚樊生物科技有限公司 Use of hypo-acylated lps for anti-oxidation and prevention/treatment of diseases

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014130540A1 (en) * 2013-02-22 2014-08-28 The Regents Of The University Of California Compositions and methods for promoting growth of beneficial microbes to treat or prevent disease or prolong life
US20160243175A1 (en) * 2013-10-03 2016-08-25 The Trustees Of The University Of Pennsylvania Compositions and methods comprising a defined microbiome and methods of use thereof
WO2016149449A1 (en) * 2015-03-18 2016-09-22 Tufts University Compositions and methods for preventing colorectal cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4763681B2 (en) 2004-03-05 2011-08-31 ベニテック インコーポレイテッド Multi-promoter expression cassette for simultaneous delivery of RNAi action mediators
TW200930405A (en) 2007-11-15 2009-07-16 Alcon Res Ltd Low density lipoprotein receptor-mediated siRNA delivery
US8324366B2 (en) 2008-04-29 2012-12-04 Alnylam Pharmaceuticals, Inc. Compositions and methods for delivering RNAI using lipoproteins
US20110071208A1 (en) 2009-06-05 2011-03-24 Protiva Biotherapeutics, Inc. Lipid encapsulated dicer-substrate interfering rna
NZ601737A (en) 2010-02-24 2013-06-28 Arrowhead Res Corp Compositions for targeted delivery of sirna
US8501930B2 (en) 2010-12-17 2013-08-06 Arrowhead Madison Inc. Peptide-based in vivo siRNA delivery system
CA2976966C (en) 2010-12-29 2021-11-09 F. Hoffmann-La Roche Ag Small molecule conjugates for intracellular delivery of nucleic acids

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014130540A1 (en) * 2013-02-22 2014-08-28 The Regents Of The University Of California Compositions and methods for promoting growth of beneficial microbes to treat or prevent disease or prolong life
US20160243175A1 (en) * 2013-10-03 2016-08-25 The Trustees Of The University Of Pennsylvania Compositions and methods comprising a defined microbiome and methods of use thereof
WO2016149449A1 (en) * 2015-03-18 2016-09-22 Tufts University Compositions and methods for preventing colorectal cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
M. KVERKA ET AL: "Oral administration of Parabacteroides distasonis antigens attenuates experimental murine colitis through modulation of immunity and microbiota composition", CLINICAL AND EXPERIMENTAL IMMUNOLOGY, vol. 163, no. 2, 19 February 2011 (2011-02-19), GB, pages 250 - 259, XP055295102, ISSN: 0009-9104, DOI: 10.1111/j.1365-2249.2010.04286.x *

Also Published As

Publication number Publication date
WO2018112365A2 (en) 2018-06-21

Similar Documents

Publication Publication Date Title
WO2018112365A3 (en) Methods of treating colorectal cancer and melanoma using parabacteroides goldsteinii
PH12019502810A1 (en) Bicyclic heterocycles as fgfr inhibitors
TW201611847A (en) Compounds and compositions for treating EGFR expressing tumors
EA201590987A1 (en) CONNECTIONS AND METHODS OF THEIR APPLICATION
EA201691845A1 (en) PHARMACEUTICAL COMPOSITIONS OF THERAPEUTICALLY ACTIVE COMPOUNDS
PH12020500371A1 (en) Spirocycle compounds and methods of making and using same
PH12016502249A1 (en) Pladienolide pyridine compounds and methods of use
EA201691844A1 (en) PHARMACEUTICAL COMPOSITIONS OF THERAPEUTICALLY ACTIVE COMPOUNDS
MX2018010993A (en) Icariin and icaritin derivatives.
MX2019013808A (en) Compounds for treatment of cancer.
MX2016009590A (en) Apilimod compositions and methods for using same.
MX2018000715A (en) Methods for treating cancer using apilimod.
MX2016009663A (en) Icariin derivatives.
PH12018501279A1 (en) Compositions comprising 15-hepe and methods of using the same
PH12020500372A1 (en) Spirocycle compounds and methods of making and using same
MX2017006026A (en) Apilimod for use in the treatment of colorectal cancer.
PH12016501838A1 (en) Compounds and their methods of use
EP3490555A4 (en) Methods and compositions to treat cancer
MX2018007468A (en) Collagen 7 compositions and methods of using the same.
MX2017017119A (en) High concentration formulation.
CY1125266T1 (en) RAD1901 FOR USE IN THE TREATMENT OF OVARIAN CANCER
WO2019028012A3 (en) Methods of using pembrolizumab and trebananib
MY182809A (en) Compositions for the treatment of kidney and/or liver disease
MX2019003002A (en) Combination therapies using indazolylbenzamide derivatives for the treatment of cancer.
MX2018013863A (en) Combination therapies using indazolylbenzamide derivatives for the treatment of cancer.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17829798

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17829798

Country of ref document: EP

Kind code of ref document: A2